Status:
COMPLETED
Biologic Basis of Liver Cancer From Chronic Hepatitis B
Lead Sponsor:
University of California, Davis
Conditions:
Hepatocellular Carcinoma
Hepatitis B, Chronic
Eligibility:
All Genders
18+ years
Brief Summary
The focus of the study is to identify viral factors and host immune responses that differentiate HBV-related HCC patients from HBV patients who have not progressed to HCC. To that end, the investigato...
Detailed Description
2\) Objectives Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide (Jemel et al CA Cancer J Clin 2011). Asian and Pacific Islander (API) Americans are perenni...
Eligibility Criteria
Inclusion
- Asian Americans
- Aged 18 years or older with a confirmed diagnosis of HCC and liver cancer from chronic hepatitis B.
- The diagnosis of liver cancer can be made with by meeting radiologic criteria for HCC or liver histology obtained through liver biopsy.
Exclusion
- Co-infection with hepatitis C virus (HCV) or HIV
- Use of immunosuppressive medications
- Inability to give informed consent
- Prisoners
- Pregnant women
- Cognitively impaired individuals or inability to provide informed consent
Key Trial Info
Start Date :
March 20 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 14 2018
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT03300414
Start Date
March 20 2017
End Date
December 14 2018
Last Update
April 11 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Davis
Sacramento, California, United States, 95817